Holak TA - Search Results

1

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Guzik K, Tomala M, Muszak D, Konieczny M, Hec A, Błaszkiewicz U, Pustuła M, Butera R, Dömling A, Holak TA. Guzik K, et al. Among authors: holak ta. Molecules. 2019 May 30;24(11):2071. doi: 10.3390/molecules24112071. Molecules. 2019. PMID: 31151293 Free PMC article. Review.

2

Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists.

Srivastava S, Beck B, Wang W, Czarna A, Holak TA, Dömling A. Srivastava S, et al. Among authors: holak ta. J Comb Chem. 2009 Jul-Aug;11(4):631-9. doi: 10.1021/cc9000218. J Comb Chem. 2009. PMID: 19548636 Free PMC article.

3

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.

Popowicz GM, Czarna A, Wolf S, Wang K, Wang W, Dömling A, Holak TA. Popowicz GM, et al. Among authors: holak ta. Cell Cycle. 2010 Mar 15;9(6):1104-11. doi: 10.4161/cc.9.6.10956. Epub 2010 Mar 15. Cell Cycle. 2010. PMID: 20237429

4

The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Popowicz GM, Dömling A, Holak TA. Popowicz GM, et al. Among authors: holak ta. Angew Chem Int Ed Engl. 2011 Mar 14;50(12):2680-8. doi: 10.1002/anie.201003863. Epub 2011 Feb 21. Angew Chem Int Ed Engl. 2011. PMID: 21341346 Free PMC article. Review.

5

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).

Zak K, Pecak A, Rys B, Wladyka B, Dömling A, Weber L, Holak TA, Dubin G. Zak K, et al. Among authors: holak ta. Expert Opin Ther Pat. 2013 Apr;23(4):425-48. doi: 10.1517/13543776.2013.765405. Epub 2013 Feb 4. Expert Opin Ther Pat. 2013. PMID: 23374098 Review.

6

The p53-MDM2/MDMX axis - A chemotype perspective.

Khoury K, Popowicz GM, Holak TA, Dömling A. Khoury K, et al. Among authors: holak ta. Medchemcomm. 2011;2:246-260. doi: 10.1039/C0MD00248H. Medchemcomm. 2011. PMID: 24466404 Free PMC article.

7

Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.

Dömling A, Holak TA. Dömling A, et al. Among authors: holak ta. Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8. doi: 10.1002/anie.201307906. Epub 2014 Jan 28. Angew Chem Int Ed Engl. 2014. PMID: 24474145 Free PMC article.

8

Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor.

Boltjes A, Huang Y, van de Velde R, Rijkee L, Wolf S, Gaugler J, Lesniak K, Guzik K, Holak TA, Dömling A. Boltjes A, et al. Among authors: holak ta. ACS Comb Sci. 2014 Aug 11;16(8):393-6. doi: 10.1021/co500026b. Epub 2014 Jul 11. ACS Comb Sci. 2014. PMID: 24983416 Free PMC article.

9

2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.

Neochoritis CG, Wang K, Estrada-Ortiz N, Herdtweck E, Kubica K, Twarda A, Zak KM, Holak TA, Dömling A. Neochoritis CG, et al. Among authors: holak ta. Bioorg Med Chem Lett. 2015 Dec 15;25(24):5661-6. doi: 10.1016/j.bmcl.2015.11.019. Bioorg Med Chem Lett. 2015. PMID: 26584879 Free PMC article.

10

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. Zak KM, et al. Among authors: holak ta. Structure. 2015 Dec 1;23(12):2341-2348. doi: 10.1016/j.str.2015.09.010. Epub 2015 Oct 22. Structure. 2015. PMID: 26602187 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page